01 Shift towards Non-Steroidal Alternatives in Radiodermatitis Treatment The shift toward non-steroidal treatment alternatives is a growing trend in the market for radiodermatitis. While corticosteroids have been commonly used to manage radiation-induced skin inflammation, their long-term use is associated with side effects such as skin thinning, delayed wound healing, and an increased risk of infections. As a result, healthcare providers and researchers are exploring safer, more sustainable treatment options. For instance, in July 2024, a study published in Molecular Medicine highlighted the significant role of gut microbiota in enhancing the effectiveness of radiotherapy while also mitigating side effects. This finding paves the way for microbiota-based therapies, which improve cancer treatment outcomes and offer potential benefits in managing radiodermatitis without relying on steroids.
02 Rising Demand for Plant-Based & Herbal Treatments in Radiodermatitis The global market is also witnessing increasing demand for plant-based and herbal remedies due to their natural composition and lower risk of adverse effects. These treatments are gaining traction as they provide soothing, anti-inflammatory, and healing benefits without the drawbacks associated with synthetic drugs. For example, in September 2022, a study published in Frontiers in Pharmacology conducted a systematic review on the use of Aloe vera for preventing radiodermatitis. The research confirmed that Aloe vera exhibits significant potential as a topical agent, effectively soothing and healing affected areas. Consequently, many individuals and healthcare providers are incorporating Aloe vera as a preferred remedy for mild to moderate cases of radiodermatitis.
February 2026 Mölnlycke Health Care launched additional clinical education initiatives to support the adoption of evidence-based wound care solutions for radiation dermatitis management in oncology centers.
October 2025 Solventum expanded its advanced wound care portfolio with new silicone dressing technologies designed to support the management of radiodermatitis and other treatment-related skin injuries.
July 2025 Stratpharma expanded global commercialization of StrataXRT®, increasing access to its topical gel for the prevention and treatment of radiation dermatitis in cancer patients.
May 2025 Mölnlycke Health Care expanded the clinical use of Mepilex® Border Flex dressings for managing radiation-induced skin damage, strengthening its wound care portfolio for oncology patients.